GLPGF Galapagos NV (PK)

Mechelen,  Belgium; 30 September 2013 - Galapagos  NV (Euronext: GLPG) announced
today  that it  has received  a transparency  notification from Delta Lloyd N.V.
pursuant  to the Belgian transparency legislation  (Belgian Act of 2 May 2007 on
the  disclosure of major  shareholdings in issuers  whose shares are admitted to
trading on a regulated market).

Galapagos  received a transparency notification  on 27 September 2013 from Delta
Lloyd  N.V.  Delta Lloyd notified that on 26 September 2013 entities under their
control  held 2,954,890 shares, which represent 9.93% of the current 29,755,302
outstanding  Galapagos  shares.   This  represents  a reduction of Delta Lloyd's
participation by 0.15% compared to the previous notification of 3,000,000 shares
owned by Delta Lloyd Asset Management N.V.

About Galapagos
Galapagos  (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with  a large pipeline of  five Phase 2 (two led  by GSK), one Phase 1, six pre-
clinical,  and more  than 20 discovery  small-molecule and  antibody programs in
cystic   fibrosis,  inflammation,  antibiotics,  metabolic  disease,  and  other
indications.
AbbVie  and Galapagos have an agreement in CF where they work collaboratively to
develop  and commercialize  oral drugs  that address  two mutations  in the CFTR
gene,  the G551D and F508del mutation.  In the field of inflammation, AbbVie and
Galapagos  have a worldwide license agreement whereby AbbVie will be responsible
for  further  development  and  commercialization  of GLPG0634 after Phase 2B.
GLPG0634  is an orally-available, selective inhibitor  of JAK1 for the treatment
of  rheumatoid arthritis and potentially  other inflammatory diseases, currently
in Phase 2B studies in RA and about to enter Phase 2 studies in Crohn's disease.
The  Galapagos Group, including fee-for-service  companies BioFocus, Argenta and
Fidelta,  has  800 employees  and  operates  facilities  in five countries, with
global headquarters in Mechelen, Belgium.  Further information at: www.glpg.com

CONTACT
Galapagos NV
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com

This   release   may  contain  forward-looking  statements,  including,  without
limitation,   statements   containing   the   words  "believes,"  "anticipates,"
"expects,"  "intends,"  "plans,"  "seeks,"  "estimates," "may," "will," "could,"
"stands  to," and  "continues," as  well as  similar expressions.  Such forward-
looking  statements may involve known and unknown risks, uncertainties and other
factors  which might cause the  actual results, financial condition, performance
or  achievements of Galapagos,  or industry results,  to be materially different
from  any  historic  or  future  results,  financial  conditions, performance or
achievements  expressed  or  implied  by  such forward-looking statements. Given
these  uncertainties, the reader is  advised not to place  any undue reliance on
such  forward-looking statements. These forward-looking statements speak only as
of  the date of publication of  this document. Galapagos expressly disclaims any
obligation  to update  any such  forward-looking statements  in this document to
reflect  any change  in its  expectations with  regard thereto  or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.

Delta Lloyd notify of 9.93% shareholding in Galapagos : http://hugin.info/133350/R/1732381/579604.pdf

[HUG#1732381]

Grafico Azioni Galapagos NV (PK) (USOTC:GLPGF)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Galapagos NV (PK) (USOTC:GLPGF)
Storico
Da Giu 2023 a Giu 2024